Health Care · Services-Medical Laboratories

CELC Celcuity Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 160345497 filings
Russell 2000

CELC at a glance

Celcuity Inc. (CELC, SEC CIK 1603454) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as October 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Celcuity Inc. (CELC) shares worth $1.2 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by BAKER BROS. ADVISORS LP on July 14, 2026 of 261,368 shares at $102.50 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
29 funds
$1.2B · +0 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly product revenue $0, unchanged YoY, as REVTORPYK shipments began September 30, 2026
  • Net loss $73.3M vs $43.8M YoY, operating loss $77.3M vs $42.8M
  • Worst cost trend: SG&A $39.8M, up 220% YoY, driven by commercialization spending
  • Cash, equivalents and short-term investments $642.7M; operating cash use $176.7M through nine months
  • Cash runway expected through 2029, with commercialization and clinical-development spending increasing

Risk Factors

  • New regulatory risk: August 2026 sNDA for PIK3CA-mutated patients may face delay, rejection, narrower labeling, or additional data requirements
  • Regulatory and compliance risk: FDA noncompliance could trigger recalls, approval withdrawal, fines, injunctions, or criminal penalties
  • Market risk: REVTORPYK faces competition from alpelisib, capivasertib, everolimus, and endocrine regimens
  • Pricing and reimbursement risk: Proposed Medicare MFN rebate models could begin January 1, 2027
  • Intellectual-property risk: Generic competition could follow patent challenges and substantially reduce REVTORPYK revenue

AI summary of the CELC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Celcuity announced financial results for the quarter ended September 30, 2026
  • Full revenue, earnings and cash-flow details are in Exhibit 99.1, the accompanying results release

Item EX-99.1: Item EX-99.1

  • REVTORPYK launch gaining access: 91% of U.S. commercial and Medicare lives covered, while 78% of 36 strategic accounts have ordered
  • Early reach broad but revenue absent: shipments began September 30, yet no product revenue recognized in Q3
Filed Oct 2, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Board expanded from 8 to 9 directors, adding David W. Gryska through the 2027 Annual Meeting
  • Gryska qualifies as Nasdaq and SEC independent director

Item EX-99.1: Item EX-99.1

  • David Gryska appointed to Celcuity’s Board, adding over 35 years of life sciences strategic and financial leadership
  • Former CFO of Incyte and Celgene, strengthening oversight as Celcuity transitions to commercial operations

Item 7.01: Regulation FD Disclosure

  • Board appointment announcement for Mr. Gryska, adding a new director to Celcuity’s governance structure
  • Audit Committee and Compensation Committee assignments, expanding his oversight responsibilities
Filed Sep 30, 2026Full analysis →

Item 8.01: Other Events

  • REVTORPYK commercially available in the U.S. for eligible HR+/HER2- advanced breast cancer patients
  • Indicated after progression following at least one metastatic-setting endocrine therapy line

Item EX-99.1: Item EX-99.1

  • REVTORPYK became commercially available in the U.S. on September 30, 2026, initiating Celcuity’s first product launch
  • FDA-approved for HR+/HER2- advanced breast cancer without detected PIK3CA mutation after at least one metastatic endocrine-therapy line

Item 7.01: Regulation FD Disclosure

  • REVTORPYK (gedatolisib) now commercially available in the U.S. for eligible breast cancer patients
  • Indication: HR+, HER2-, locally advanced or metastatic disease after endocrine-therapy progression

AI summaries of CELC 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CELC

Don't miss the next CELC filing

  • Alerts as it files. A push when CELC files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CELC, by share count.
  • Ask anything. An AI agent that reads every CELC filing and answers with sources.

CELC alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Furcht LeoMOct 7, 2026$7.60
Furcht LeoMOct 7, 2026-
GRYSKA DAVID WAOct 1, 2026-
Laing Lance G.AAug 14, 2026-
Sullivan Brian F.AAug 14, 2026-
Sullivan Brian F.AAug 14, 2026-
Hahne VickyAAug 14, 2026-
Laing Lance G.AAug 14, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$66.2M-$113.3M-$172.2M
Net Income-$63.8M-$111.8M-$177.0M
Balance Sheet
Total Assets-$245.1M$466.6M
Equity$139.8M$115.6M$100.6M
ROE-45.6%-96.7%-176.1%
Per Share
EPS$-2.69$-2.83$-3.79
Cash Flow
Operating CF-$53.8M-$83.5M-$153.3M
CapEx$98K$250K$249K

Source: XBRL data in Celcuity Inc. (CELC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CELC share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CELC shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202629$1.20B
Q2 202629$1.48B
Q1 202631$1.35B
Q4 202528$1.24B
Q3 202528$518.7M
Q2 202522$104.3M
Q1 202517$58.4M
Q4 202414$61.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 198 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CELC filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
4Oct 9, 2026--
4Oct 5, 2026--
8-KOct 2, 2026Analysis-
8-KSep 30, 2026Analysis-
8-KAug 26, 2026Analysis-
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
10-QAug 13, 2026Analysis
8-KAug 13, 2026Analysis-
SC 13GAug 11, 2026-
4Jul 16, 2026--
SC 13GJul 16, 2026-
8-KJul 15, 2026Analysis-
8-KJul 15, 2026Analysis-
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 9, 2026-
4Jun 9, 2026-
4Jun 9, 2026-
4Jun 9, 2026-
4Jun 9, 2026-
4Jun 9, 2026-

Related Health Care companies

All Health Care →

CELC SEC filings: frequently asked questions

Which institutions hold CELC stock?

As of September 30, 2026, the largest Celcuity Inc. (CELC) holders among the 13F filers tracked by SignalX were BlackRock ($252.7 million), State Street Corp ($163.5 million), Vanguard Capital Management LLC ($154.4 million), Bank of America Corp ($135.9 million), Morgan Stanley ($121.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did CELC report in its latest 8-K?

Celcuity Inc. (CELC) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Celcuity announced financial results for the quarter ended September 30, 2026.

What are the latest CELC SEC filings?

Celcuity Inc. (CELC) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on October 9, 2026.

What is CELC's SEC CIK number?

Celcuity Inc. (CELC)'s SEC Central Index Key (CIK) is 1603454. EDGAR lists every CELC filing under that number.

Ask anything about CELC

The research agent reads CELC's filings, financials, insider trades and 13F holders, then answers with sources.